TOKYO, Mar 23 (Pulse News Wire) – Anges,inc. (4563.T) reported its consolidated financial results for the fiscal year ending December 31, 2025, showing a net loss of ¥23.005 billion compared to ¥28.128 billion in the previous year.
The company's operating profit improved due to increased revenues from testing services and reduced amortization expenses. For the fiscal year 2026, AnGes expects consolidated revenue of ¥1.300 billion, with projected operating losses of -¥5.123 billion and a net loss of ¥10.25 billion.
Key factors driving the anticipated decline include higher costs associated with product manufacturing and clinical trial activities. Additionally, the company highlighted ongoing development efforts for its ARDS treatment drug, which is currently undergoing Phase IIa clinical trials in the United States.
FDA Fast Track designation allows for more frequent communication and expedited review processes, potentially accelerating approval timelines.
🟡 Confidence: Standard AI-translated content.